Pliant Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Pliant Therapeutics

25/02/2023 03:04

* Pliant Therapeutics Inc  PLRX.OQ   PLRX.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
27 (estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 28.4% decrease in revenue to $1.431 million from $2
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pliant Therapeutics
Inc
is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $45​, above​ its last closing price
of $31.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.74       -0.74      -0.65     Beat    12.3
 Jun. 30 2022  -0.82       -0.81      -0.82     Missed  -1
 Mar. 31 2022  -0.73       -0.75      -0.78     Missed  -4​
 Dec. 31 2021  -0.76       -0.76      -0.68     Beat    10.4
 ​​Sep.        -0.68       -0.69      -0.75     Missed  -8.7
 30 2021                                                
 Jun. 30 2021  -0.67       -0.67      -0.64     Beat    4.4​
 Mar. 31 2021  -0.64       -0.60      -0.64     Missed  -6
 Dec. 31 2020              -0.71      -0.54     Beat    24.2
 This summary was machine generated February 25 at 03:04 GMT. 
All figures in US dollars  unless otherwise stated